ArticleFrontiers in pharmacology2025
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploration of Phytochemical Constituents inAntioxidants (Basel, Switzerland) · 2026Article
- Anti-Obesity Effects of Soy Peptides In Vivo: A Meta-Analysis of Randomized Controlled Trials.Foods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The objective of this study was to demonstrate the anti-obesity and anti-inflammatory effects of Methods: The anti-obesity and anti-inflammatory potential of Results: In HFD-induced obese mice, NJFE significantly reduced adipocyte hypertrophy, dyslipidemia, and glucose intolerance, while alleviating adipose tissue inflammation. In 3T3-L1 adipocytes, NJFE suppressed adipogenic differentiation and downregulated adipogenesis-related genes. In RAW264.7 macrophages stimulated with LPS, NJFE markedly reduced inflammatory responses. Furthermore, NJFE attenuated inflammatory responses in 3T3-L1 adipocytes exposed to conditioned medium derived from LPS-stimulated RAW264.7 cells. NJFE also improved mitochondrial function in adipocytes. Conclusion: These findings demonstrate that NJFE not only improves obesity but also alleviates obesity-induced inflammation, supporting its potential as a promising natural therapeutic candidate for the prevention and treatment of obesity and related metabolic disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.